Pharmaceutical executive Peter A. DiBiaso, MHA, a triathlete who has successfully completed the grueling Ironman, learned at age 49 he had early-onset Parkinson’s disease. He shares his experiences—and triumphs—in this episode.
What started as a small tremor in his right hand and a stiffness in his right ankle ended up changing his life.
It was a blow, but he knew what to do: The diagnosis brought his personal and professional life full circle. Five years later, he reports minimal disease progression. He is doing well and remains incredibly active. Other than well-managed medication, to what does he attribute his success so far?
He has also been involved in six clinical trials—both interventional and observational. He knew the value as an industry insider. Now, he appreciates the value from the patient perspective—and he better understands the frustrations patients face. It too often falls on the patients to initiate discussions about clinical trials. That’s fine for him, he says, but what about those who don’t know trials are available?
His professional life has focused on patient recruitment issues, so he brings a 360-degree perspective. Sponsors, he says, need to focus on more than the academic and clinical elements; they must address real-world issues and trial participants’ challenges—even those that seem minor, like parking.
It comes down to patient-centricity, he explains—putting patients at the center of the clinical research enterprise. It is becoming more common, but there’s still a long way to go.
Peter DiBiaso, MHA, is a consultant to drug development companies and has worked at Pfizer, Shire, Vertex, and IQVIA. He is married and has two children, and he and his family split their time between Paris and Boston.
View all episodes
By WCG
5
1313 ratings
Pharmaceutical executive Peter A. DiBiaso, MHA, a triathlete who has successfully completed the grueling Ironman, learned at age 49 he had early-onset Parkinson’s disease. He shares his experiences—and triumphs—in this episode.
What started as a small tremor in his right hand and a stiffness in his right ankle ended up changing his life.
It was a blow, but he knew what to do: The diagnosis brought his personal and professional life full circle. Five years later, he reports minimal disease progression. He is doing well and remains incredibly active. Other than well-managed medication, to what does he attribute his success so far?
He has also been involved in six clinical trials—both interventional and observational. He knew the value as an industry insider. Now, he appreciates the value from the patient perspective—and he better understands the frustrations patients face. It too often falls on the patients to initiate discussions about clinical trials. That’s fine for him, he says, but what about those who don’t know trials are available?
His professional life has focused on patient recruitment issues, so he brings a 360-degree perspective. Sponsors, he says, need to focus on more than the academic and clinical elements; they must address real-world issues and trial participants’ challenges—even those that seem minor, like parking.
It comes down to patient-centricity, he explains—putting patients at the center of the clinical research enterprise. It is becoming more common, but there’s still a long way to go.
Peter DiBiaso, MHA, is a consultant to drug development companies and has worked at Pfizer, Shire, Vertex, and IQVIA. He is married and has two children, and he and his family split their time between Paris and Boston.
31,966 Listeners
111,115 Listeners
55,947 Listeners
365,305 Listeners
14,442 Listeners
28,345 Listeners
15,285 Listeners
6,726 Listeners
12 Listeners